Advertisement

Intravitreal ranibizumab in retinal macroaneurysm

  • Andrea R. Wenkstern
  • Heike Petersen
Case Report

Abstract

Purpose

To present the effect of intravitreal ranibizumab (Lucentis®) therapy in a patient suffering from retinal macroaneurysm.

Methods

Case report. An 82-year-old female patient was diagnosed with retinal macroaneurysm of the inferior temporal artery with macular edema. Functional and morphological data at baseline and at 4 weeks, 3 months, and 5 months after the initiation of therapy with two intravitreal ranibizumab (Lucentis®) injections followed by focal argon laser coagulation surrounding the retinal macroaneurysm are presented.

Results

Best-corrected visual acuity improved from 20/50 at baseline to 20/20 at 3-month follow-up and maintained stable at 20/25 through 5-month follow-up. Central retinal thickness measured by optical coherence tomography decreased from 510 µm at baseline to 148 µm at 5-month follow-up. Fluorescein angiography demonstrated closure of the retinal macroaneurysm at 6-week follow-up. No ocular or systemic side effects were detected.

Conclusions

Intravitreal ranibizumab (Lucentis®) therapy may close the retinal macroaneurysm leading to resolution of the associated macular edema and consequently visual improvement. To our knowledge, this is the first case of a retinal macroaneurysm benefiting from treatment with intravitreal ranibizumab (Lucentis®). The observed results warrant further investigation.

Keywords

Bevacizumab Macular Edema Ranibizumab Macular Hole Diabetic Macular Edema 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Notes

Financial conflicts or relationships

None.

References

  1. 1.
    Chew EY, Murphy RP (2005) Acquired retinal macroaneurysms. In: Ryan SJ (ed) Retina. Vol 2; Medical Retina. St. Louis: Mosby, 1499–1502Google Scholar
  2. 2.
    Lewis RA, Norton EW, Gass JD (1976) Acquired arterial macroaneurysms of the retina. Br J Ophthalmol 60(1):21–30CrossRefPubMedGoogle Scholar
  3. 3.
    Tsujikawa A, Sakamoto A, Ota M, Oh H, Miyamoto K, Kita M, Yoshimura N (2009) Retinal structural changes associated with retinal arterial macroaneurysm examined with optical coherence tomography. Retina 29(6):782–792CrossRefPubMedGoogle Scholar
  4. 4.
    Brown DM, Sobol WM, Folk JC, Weingeist TA (1994) Retinal arteriolar macroaneurysms: long-term visual outcomes. Br J Ophthalmol 78(7):534–538CrossRefPubMedGoogle Scholar
  5. 5.
    Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, Kim RY, Marina Study Group (2006) Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 355(14):1419–1431CrossRefPubMedGoogle Scholar
  6. 6.
    Chanana B, Azad RV (2009) Intravitreal bevacizumab for macular edema secondary to retinal macroaneurysm. Eye 23(2):493–494CrossRefPubMedGoogle Scholar
  7. 7.
    Jonas JB, Schmidbauer M (2009) Intravitreal bevacizumab for retinal macroaneurysm. Acta Ophthalmol Sep11. [Epub ahead of print]Google Scholar
  8. 8.
    Chun DW, Heier JS, Topping TM, Duker JS, Bankert JM (2006) A pilot study of multiple intravitreal injections of ranibizumab in patients with center-involving clinically significant diabetic macular edema. Ophthalmology 113(10):1702–1712CrossRefGoogle Scholar
  9. 9.
    Pieramici DF, Rabena M, Castellarin AA, Nasir M, See R, Norton T, Sanchez A, Risard S, Avery RL (2008) Ranibizumab for the treatment of macular edema associated with perfused central retinal vein occlusions. Ranibizumab in vein occlusion. Ophthalmology 115(10):47–54CrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2010

Authors and Affiliations

  1. 1.Eye Center UzwilUzwilSwitzerland
  2. 2.Eye Center FrauenfeldFrauenfeldSwitzerland
  3. 3.UzwilSwitzerland

Personalised recommendations